AUTHOR=Long Sarah Alice , Muir Virginia S. , Jones Britta E. , Wall Valerie Z. , Ylescupidez Alyssa , Hocking Anne M. , Pribitzer Stephan , Thorpe Jerill , Fuchs Bryce , Wiedeman Alice E. , Tatum Megan , Lambert Katharina , Uchtenhagen Hannes , Speake Cate , Ng Bernard , Heubeck Alexander T. , Torgerson Troy R. , Savage Adam K. , Maldonado Michael A. , Ray Neelanjana , Khaychuk Vadim , Liu Jinqi , Linsley Peter S. , Buckner Jane H. TITLE=Abatacept increases T cell exhaustion in early RA individuals who carry HLA risk alleles JOURNAL=Frontiers in Immunology VOLUME=15 YEAR=2024 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1383110 DOI=10.3389/fimmu.2024.1383110 ISSN=1664-3224 ABSTRACT=

Exhausted CD8 T cells (TEX) are associated with worse outcome in cancer yet better outcome in autoimmunity. Building on our past findings of increased TIGIT+KLRG1+ TEX with teplizumab therapy in type 1 diabetes (T1D), in the absence of treatment we found that the frequency of TIGIT+KLRG1+ TEX is stable within an individual but differs across individuals in both T1D and healthy control (HC) cohorts. This TIGIT+KLRG1+ CD8 TEX population shares an exhaustion-associated EOMES gene signature in HC, T1D, rheumatoid arthritis (RA), and cancer subjects, expresses multiple inhibitory receptors, and is hyporesponsive in vitro, together suggesting co-expression of TIGIT and KLRG1 may broadly define human peripheral exhausted cells. In HC and RA subjects, lower levels of EOMES transcriptional modules and frequency of TIGIT+KLRG1+ TEX were associated with RA HLA risk alleles (DR0401, 0404, 0405, 0408, 1001) even when considering disease status and cytomegalovirus (CMV) seropositivity. Moreover, the frequency of TIGIT+KLRG1+ TEX was significantly increased in RA HLA risk but not non-risk subjects treated with abatacept (CTLA4Ig). The DR4 association and selective modulation with abatacept suggests that therapeutic modulation of TEX may be more effective in DR4 subjects and TEX may be indirectly influenced by cellular interactions that are blocked by abatacept.